Id: acc4594
Group: 1sens
Protein: NOS3
Gene Symbol: NOS3
Protein Id: P29474
Protein Name: NOS3_HUMAN
PTM: phosphorylation
Site: Ser1177
Site Sequence: EVTSRIRTQSFSLQERQLRGA
Disease Category: Cancer
Disease: Colorectal Cancer
Disease Subtype:
Disease Cellline: DLD-1
Disease Info:
Drug: Oxaliplatin
Drug Info: "Oxaliplatin is a chemotherapy drug used to treat various types of cancer, such as colorectal cancer."
Effect: resist
Effect Info: Downregulation of NOS3 phosphorylation level overcomes the resistance of cancer cells to Oxaliplatin. CBD can reduce the phosphorylation level of NOS3.
Note:
Score: 5.0
Pubmed(PMID): 31195721
Sentence Index:
Sentence:

Sequence & Structure:

MGNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLTQPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDDPPELFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKAFDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATILVRLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPPPGWVRDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRYEEWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEAGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTNSP

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
NOS3 TILARGININE ACETATE Nitric oxide synthase inhibitor 3 Terminated Shock ClinicalTrials
NOS3 TILARGININE Nitric oxide synthase inhibitor 3 Terminated Shock ClinicalTrials
NOS3 TILARGININE Nitric oxide synthase inhibitor 2 Terminated anemia (phenotype) ClinicalTrials
NOS3 TILARGININE Nitric oxide synthase inhibitor 2 Completed sickle cell anemia ClinicalTrials
ClinicalTrials
NOS3 TILARGININE Nitric oxide synthase inhibitor 2 Completed hyperlipidemia ClinicalTrials
NOS3 TILARGININE Nitric oxide synthase inhibitor 1 Terminated HIV infection ClinicalTrials
NOS3 TILARGININE Nitric oxide synthase inhibitor 1 Withdrawn hypoxia ClinicalTrials
NOS3 TILARGININE Nitric oxide synthase inhibitor 1 Completed serum lipopolysaccharide activity ClinicalTrials
NOS3 TILARGININE Nitric oxide synthase inhibitor 1 Completed sarcopenia ClinicalTrials
NOS3 TILARGININE Nitric oxide synthase inhibitor 1 Completed breast cancer ClinicalTrials
NOS3 TILARGININE Nitric oxide synthase inhibitor 1 Completed sickle cell anemia ClinicalTrials
ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
NOS3-Ser1177
Cancer Intensity
BRCA 0.71
COAD 0.399
HGSC 1.182
ccRCC 0.059
GBM -0.83
HNSC 0.225
LUAD 0.965
LUSC 0.783
non_ccRCC -1.984
PDAC -0.216
UCEC -1.292

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: